Analysts say Pfizer could use its strong connections within the Trump administration to bolster its case, with CEO Albert ...
TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...
Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from ...
As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn acquisition of ...
The pharmaceutical sector is witnessing a high-stakes confrontation as Pfizer finds itself embroiled in a fierce bidding ...
Investor's Business Daily on MSN
AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%
AbbVie dipped early Friday, though the drug giant easily beat third-quarter forecasts on the back of its immunology meds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback